Ocular Therapeutix Inc
$ 12.56
-1.18%
26 Dec - close price
- Market Cap 2,675,876,000 USD
- Current Price $ 12.56
- High / Low $ 12.75 / 12.48
- Stock P/E N/A
- Book Value 1.48
- EPS -1.43
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.82 %
- 52 Week High 16.44
- 52 Week Low 5.79
About
Ocular Therapeutix, Inc. is a biopharmaceutical innovator specializing in the development and commercialization of novel therapies for ophthalmic diseases, leveraging its proprietary bioresorbable hydrogel platform technology. Based in Bedford, Massachusetts, the company focuses on addressing unmet medical needs in eye care with a strong portfolio designed to enhance patient adherence and therapeutic effectiveness. With a commitment to advancing research and development, Ocular Therapeutix stands as a key player in the ophthalmic market, striving to improve patient outcomes and solidify its position in a rapidly evolving industry.
Analyst Target Price
$24.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-10 | 2024-11-05 | 2024-08-07 | 2024-05-07 | 2024-03-11 | 2023-11-07 | 2023-08-07 | 2023-05-08 | 2023-03-06 |
| Reported EPS | -0.38 | -0.39 | -0.3724 | -0.29 | -0.22 | -0.26 | -0.7 | -0.35 | -0.17 | -0.26 | -0.39 | -0.24 |
| Estimated EPS | -0.37 | -0.35 | -0.28 | -0.22 | -0.24 | -0.22 | -0.19 | -0.3 | -0.29 | -0.3 | -0.26 | -0.25 |
| Surprise | -0.01 | -0.04 | -0.0924 | -0.07 | 0.02 | -0.04 | -0.51 | -0.05 | 0.12 | 0.04 | -0.13 | 0.01 |
| Surprise Percentage | -2.7027% | -11.4286% | -33% | -31.8182% | 8.3333% | -18.1818% | -268.4211% | -16.6667% | 41.3793% | 13.3333% | -50% | 4% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3205 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCUL
2025-12-26 08:08:39
Assenagon Asset Management S.A. significantly reduced its stake in Ocular Therapeutix, Inc. by selling 148,100 shares, bringing its total holdings to 45,600 shares. This move by Assenagon comes as other institutional investors like Adage Capital Partners and Invesco Ltd. increased their positions, while company insiders also sold a combined 31,287 shares. Analysts currently rate Ocular Therapeutix with a "Moderate Buy" and a consensus target price of $22.56.
2025-12-26 07:08:40
Ocular Therapeutix (NASDAQ:OCUL) shares have moved above their 50-day moving average, trading at $12.71 against a 50-day MA of $12.28, on heavy volume. The company holds a "Moderate Buy" consensus from analysts with a target price of $22.56, despite remaining unprofitable and recent insider share sales. Institutional investors own approximately 59% of the stock, while insiders have sold over 31,000 shares in the last 90 days.
2025-12-19 09:09:27
Ocular Therapeutix's (OCUL) stock dropped 10.9% after the company announced its plan to pursue a single-trial New Drug Application (NDA) for its wet AMD candidate AXPAXLI, leveraging positive year-one data from the SOL-1 Phase 3 trial. This strategic pivot, influenced by FDA feedback, could accelerate market entry but also heightens regulatory risks around the Q1 2026 data readout. The change sharpens the near-term catalyst while concentrating the company's investment narrative on AXPAXLI's success.
2025-12-18 04:09:25
Ocular Therapeutix (OCUL) has accelerated its FDA filing plan for AXPAXLI in wet AMD based on positive Phase 3 data, leading to a valuation that suggests it is 43.2% undervalued. Despite a weak 5-year return, the company has shown strong long-term momentum with a 3-year total shareholder return of 395.31% and analysts see considerable upside. The potential approval of AXPAXLI with a superiority label and longer dosing intervals could capture significant market share and drive substantial revenue growth in the expanding market for ophthalmic disorders.
2025-12-17 11:10:30
Ocular Therapeutix (OCUL) has accelerated its FDA filing for AXPAXLI in wet AMD based on positive Phase 3 data, leading to a "narrative" valuation of $24.17 against its current $13.72 share price, suggesting it is undervalued. The drug, potentially offering longer dosing intervals and superiority, could capture significant market share in the growing wet AMD market. Although the stock has seen substantial gains, analysts still see considerable upside, raising questions about whether the market has fully priced in its potential.
2025-12-16 12:19:15
RBC Capital has increased its price target for Ocular Therapeutix (OCUL) to $24 from $17, while reiterating an Outperform rating on the stock. This adjustment reflects an updated outlook from the analysts. Ocular Therapeutix is a biopharmaceutical company focused on developing therapies for various ophthalmic conditions.
